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Abstract
To identify the roles of the two nucleotide-binding folds (NBFs) in the function of human P-glycoprotein, a multidrug
transporter, we mutated the key lysine residues to methionines and the cysteine residues to alanines in the Walker A (WA)
motifs (the core consensus sequence) in the NBFs. We examined the effects of these mutations on N-ethylmaleimide (NEM)
and ATP binding, as well as on the vanadate-induced nucleotide trapping with 8-azido-[K-32P]ATP. Mutation of the WA
lysine or NEM binding cysteine in either of the NBFs blocked vanadate-induced nucleotide trapping of P-glycoprotein.
These results suggest that if one NBF is non-functional, there is no ATP hydrolysis even if the other functional NBF contains
a bound nucleotide, further indicating the strong cooperation between the two NBFs of P-glycoprotein. However, we found
that the effect of NEM modification at one NBF on ATP binding at the other NBF was not equivalent, suggesting a non-
equivalency of the role of the two NBFs in P-glycoprotein function. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
P-Glycoprotein functions as an ATP-dependent ef-
£ux pump that extrudes cytotoxic drugs from cells
before the drugs reach their intracellular targets, and
in this way confers multidrug resistance on the can-
cer cells [1^3]. P-Glycoprotein is a member of the
ABC transporter superfamily, characterized by two
multiple transmembrane domains and two nucleo-
tide-binding folds (NBFs) [4].
Both NBFs of P-glycoprotein can hydrolyze nu-
cleotides, and their ATPase activity is necessary for
drug transport [5^9]. Mutation of the lysine residue
in the Walker A (WA) motif of either NBF abolishes
the ATPase activity of P-glycoprotein and its ability
to confer multidrug resistance [10^12]. This lysine
residue is predicted to interact with the phosphoryl
moiety of the bound nucleotide [13,14]. The WA mo-
tifs of P-glycoprotein also contain cysteine residues
and covalent modi¢cation of either of these cysteine
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residues has been shown to be su⁄cient to inactivate
the ATPase activity of P-glycoprotein [15^17]. Fur-
thermore, vanadate-induced trapping of a nucleotide
at just one NBF is su⁄cient to inhibit this ATPase
activity [7]. These results suggest that the NBFs al-
ternate in steady-state catalysis [8], and mutations
and modi¢cations in the WA motif of either of the
NBFs inhibit a catalytic cycle. Alternatively, muta-
tions or modi¢cations in one NBF might prevent the
hydrolysis of even a single ATP at the other (still
intact) NBF.
Vanadate-induced nucleotide trapping is useful in
the analysis of ATP hydrolysis by ABC transporter
proteins [9,18,19]. Hydrolysis of a single ATP may be
enough to trap the nucleotide in the catalytic site in
the presence of vanadate. Using this technique, it
may be possible to determine a single ATP hydrolytic
event during the catalytic cycle. We examined the
e¡ect of mutating the lysine and cysteine residues
within the WA motifs of human P-glycoprotein and
the interaction of NEM with both ATP binding and
vanadate-induced nucleotide trapping. We demon-
strate that NEM modi¢cation or mutation of the
WA lysine of a single NBF is su⁄cient to prevent
vanadate-induced nucleotide trapping presumably
at the other (intact) NBF. However, we ¢nd that
the cooperative e¡ect of NEM modi¢cation at one
NBF on ATP binding at the other NBF is not equiv-
alent.
2. Materials and methods
2.1. Materials
8-Azido-[K-32P]ATP was purchased from ICN Bio-
medicals. Monoclonal antibody C219 was obtained
from Centocor.
2.2. Construction of mutants and expression vectors
Sculptor in vitro mutagenesis system (Amersham)
was used to introduce amino acid substitutions. P-
Glycoprotein-S, in which a 15 amino acid S-tag pep-
tide derived from pancreatic ribonuclease A is fused
to the C terminus of P-glycoprotein, was constructed
by fusing of a DNA fragment containing the S-tag
with a His-tag from pET-29b plasmid (Novagen).
This fusion did not a¡ect the function of P-glycopro-
tein, because the pattern and degree of multidrug
resistance conferred by P-glycoprotein-S were similar
to those conferred by P-glycoprotein (data not
shown).
2.3. Cell culture, transfection, and drug resistance
assay
An expression vector, pCAGGS [20], was used for
transient expression. Human cultured cells HEK293
were transfected by human MDR1 expression vec-
tors with LipofectAMINE (Gibco). Membrane pro-
teins were prepared 3 days after transfection as de-
scribed previously [19].
2.4. Vanadate-induced trapping of
8-azido-[K-32P]ATP and photoa⁄nity labeling
of P-glycoprotein
In a study of the e¡ect of NEM on vanadate-in-
duced nucleotide trapping, membrane proteins (20
Wg) were incubated with or without NEM for 10
min at 20‡C. Dithiothreitol was added to a ¢nal con-
centration of 400 mM, and the membrane proteins
were precipitated by centrifugation. Membrane pro-
teins were suspended in 400 Wl of 40 mM Tris-HCl
bu¡er (pH 7.5) containing 100 WM EGTA and pre-
cipitated again by centrifugation. Membrane proteins
were then reacted with 5 WM 8-azido-[K-32P]ATP in
the presence of 20 WM verapamil, 200 WM vanadate,
3 mM MgSO4, 2 mM ouabain, 0.1 mM EGTA, and
40 mM Tris-Cl (pH 7.5) in a total volume of 10 Wl
for 10 min at 37‡C. The reactions were stopped by
addition of 400 Wl of ice-cold Tris-EGTA bu¡er (0.1
mM EGTA, 40 mM Tris-Cl (pH 7.5)), and free ATP,
Mg2, and vanadate were removed after centrifuga-
tion (15 000Ug, 10 min, 4‡C). The pellet was washed
in the same bu¡er and resuspended in 8 Wl of Tris-
EGTA bu¡er, placed on ice, and irradiated for 5 min
(V= 254 nm, 5.5 mW/cm2). Samples were analyzed as
described previously [18]. Experiments were done in
triplicate.
2.5. ATP binding of P-glycoprotein
Membrane proteins (about 20 Wg) prepared from
cells expressing similar amounts of P-glycoprotein-S
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or its mutant proteins were incubated with 5 WM 8-
azido-[K-32P]ATP in the presence of 3 mM MgSO4,
2 mM ouabain, 0.1 mM EGTA, and 40 mM Tris-Cl
(pH 7.5) in a total volume of 10 Wl at 0‡C for 5 min.
The mixture was then irradiated with a UV lamp for
5 min without removing free 8-azido-[K-32P]ATP.
The labeled membranes were then made soluble
with 10 mM Tris-HCl containing 1% Nonidet-P40,
0.1% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate, 150 mM NaCl, and 0.5 mM EDTA, and P-
glycoprotein-S was precipitated with S-protein agar-
ose (Novagen). The S-tag peptide and the 104 amino
acid S-protein derived from pancreatic ribonuclease
A form a speci¢c and strong complex. Experiments
were done in triplicate.
3. Results
3.1. Inhibition of vanadate-induced nucleotide trapping
in P-glycoprotein by NEM
When membrane proteins containing human P-
glycoprotein were incubated with vanadate, Mg2,
verapamil, and 5 WM 8-azido-[K-32P]ATP, a 170
kDa protein was speci¢cally photoa⁄nity-labeled
(Fig. 1). For such labeling of P-glycoprotein, both
vanadate and Mg2 are needed, and verapamil is
stimulatory [19]. Nucleotide trapping in P-glycopro-
tein was inhibited by NEM in a concentration-de-
pendent way, and was inhibited completely by 10
WM NEM (Fig. 1A). The C431A/C1074A double-
mutant form of P-glycoprotein, in which the cysteine
residues of the WA motif in both NBFs were re-
placed by alanine, trapped nucleotides even after
treatment with 100 WM NEM (Fig. 1B). Also, these
cysteine-to-alanine mutations did not a¡ect the func-
tion of P-glycoprotein, because the pattern and de-
gree of multidrug resistance conferred by the C431A/
C1074A double-mutant form were similar to those
conferred by the wild-type protein (data not shown).
By contrast, vanadate-induced nucleotide trapping of
the C431A and C1074A mutant forms, in which the
cysteine residue of the WA motif in only one of the
NBFs was replaced by alanine, was a¡ected by NEM
(Fig. 1C,D). Nucleotide trapping with the C431A
mutant form was inhibited by 10 WM NEM (Fig.
1C), and nucleotide trapping with the C1074A mu-
tant form was inhibited by 50 WM NEM (Fig. 1D).
Fig. 1. E¡ects of NEM on vanadate-induced nucleotide trap-
ping in P-glycoprotein. Plasma membrane proteins (about 20
Wg) from stable KB-3-1 transfectants expressing equivalent
amounts of the wild-type human P-glycoprotein (A), the
C431A/C1074A double-mutant form, in which the cysteine resi-
dues of Walker A in both NBFs were replaced by alanine (B),
or the C431A (C) or C1074A (D) single-mutant form were
treated with NEM at 1 WM (lane 2), 10 WM (lane 3), 50 WM
(lane 4), or 100 WM (lane 5), or with NEM (lane 1). Then
membrane proteins were reacted with 5 WM 8-azido-[K-32P]ATP
in the presence of 20 WM verapamil, 200 WM vanadate, 3 mM
MgSO4, 2 mM ouabain, and 0.1 mM EGTA, and analyzed as
described in Section 2. Experiments were done in triplicate.
Fig. 2. E¡ects of NEM on labeling with biotin maleimide. Plas-
ma membrane proteins (about 20 Wg) from HEK293 cells tran-
siently expressing equivalent amounts of P-glycoprotein-S (in
which an S-tag is fused to the C terminus of P-glycoprotein)
and its cysteine-to-alanine mutants were incubated with 100 WM
NEM and then reacted with 5 WM biotin maleimide at 20‡C. P-
Glycoprotein-S was precipitated with S-protein agarose and an-
alyzed as described in Section 2. A, P-glycoprotein-S; B,
C431A/C1074A; C, C431A; D, C1074A. Experiments were
done in duplicate.
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3.2. Modi¢cation of the Walker A cysteines by NEM
To con¢rm the NEM modi¢cation of the cysteine
residues of the WA motifs, the e¡ects of NEM on
labeling of P-glycoprotein with biotin maleimide
were examined. P-Glycoprotein-S was labeled by
5 WM biotin maleimide and speci¢cally inhibited by
the presence of 100 WM NEM (Fig. 2A), but the
C431A/C1074A mutant form was labeled little if at
all (Fig. 2B). The C431A and C1074A mutant forms
were also both labeled in an NEM-dependent man-
ner by biotin maleimide (Fig. 2C,D), suggesting that
biotin maleimide at a concentration of 5 WM specif-
ically and uniformly labels the WA cysteines in both
NBFs, as previously reported [16]. These results
strongly indicate that the cysteines of the WA motifs
in both NBFs are responsible for the e¡ects of NEM
on vanadate-induced ATP trapping shown in Fig. 1.
3.3. E¡ects of NEM on ATP binding
The e¡ects of NEM on 8-azido-ATP binding were
examined. 8-Azido-ATP binding with the wild type
P-glycoprotein was inhibited by 100 WM NEM (Fig.
3A). 8-Azido-ATP binding with the C431A/C1074A
mutant form was not inhibited by 100 WM NEM, but
possibly increased (Fig. 3B), whereas 8-azido-ATP
binding of the C431A mutant form appeared not
to be a¡ected (Fig. 3C). However, ATP binding to
the C1074A mutant form was signi¢cantly reduced
by treatment with 100 WM NEM (Fig. 3D), similar to
the wild-type P-glycoprotein.
3.4. Vanadate-induced nucleotide trapping and
ATP binding in K433M and K1076M mutant
P-glycoproteins
To further examine the roles of the two NBFs in
the function of P-glycoprotein, we constructed three
other mutants, K433M, K1076M, and K433M/
K1076M, in which the lysine residue in the WA motif
of either or both NBFs was replaced by methionine.
Membranes prepared from cells expressing similar
Fig. 3. E¡ects of NEM on ATP binding with P-glycoprotein.
Plasma membrane proteins (about 20 Wg) from HEK293 cells
transiently expressing equivalent amounts of P-glycoprotein-S
and its cysteine-to-alanine mutant forms were incubated in the
presence or absence of 100 WM NEM. Membrane proteins were
then reacted with 5 WM 8-azido-[K-32P]ATP at 0‡C for 5 min,
for photoa⁄nity labeling. The labeled membranes were then
made soluble with detergents. P-Glycoprotein-S was precipitated
with S-protein agarose and analyzed as described in Section 2.
A, P-glycoprotein-S; B, C431A/C1074A; C, C431A; D,
C1074A. Experiments were done in triplicate.
Fig. 4. Immunoblot analysis (A), vanadate-induced nucleotide
trapping (B), and 8-azido-ATP binding (C) of wild-type protein
and lysine-to-methionine mutants of P-glycoprotein-S. Lanes: 1,
cells not transfected; 2, P-glycoprotein-S; 3, K433M; 4,
K1076M; 5, K433M/K1076M. (A) Membrane proteins (about
20 Wg) from HEK293 cells expressing equivalent amounts of
di¡erent forms of P-glycoprotein-S were separated on 7% SDS-
PAGE, and P-glycoprotein-S and mutants detected by immuno-
blotting with monoclonal antibody C219. (B) Membrane pro-
teins were reacted with 5 WM 8-azido-[K-32P]ATP in the pres-
ence of 20 WM verapamil, 200 WM vanadate, 3 mM MgSO4,
2 mM ouabain, and 0.1 mM EGTA for 10 min at 37‡C, and
analyzed as described in Section 2. (C) Membrane proteins
were reacted with 5 WM 8-azido-[K-32P]ATP at 0‡C, for photo-
a⁄nity labeling. The labeled membranes were then made solu-
ble with detergents. P-Glycoprotein-S was precipitated and ana-
lyzed as described in Section 2.
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amounts of the wild-type and mutant forms of P-
glycoprotein-S (Fig. 4A) were used for studying the
interaction with ATP. The three mutant proteins did
not trap nucleotide in the presence of vanadate (Fig.
4B). This is consistent with previous reports suggest-
ing that the lysine residues in the WA motifs in both
NBFs are important in the function of P-glycopro-
tein [10^12]. The e¡ect of these mutations on 8-azi-
do-ATP binding is also shown in Fig. 4C. As previ-
ously reported all these mutants bound ATP,
although the binding to the K433M/K1076M dou-
ble-mutant form appeared substantially reduced
(lane 5).
4. Discussion
NEM modi¢cation of either of the NBFs blocks
vanadate-induced nucleotide trapping in P-glycopro-
tein. A similar e¡ect is also observed by mutation of
either of the WA lysines suggesting an equivalent and
cooperative e¡ect of the two domains and that abol-
ishing function at either NBF is su⁄cient to prevent
the hydrolysis of a single bound nucleotide at the
other NBF. However, although NEM modi¢cation
of NBF2 did not impair 8-azido-ATP binding of P-
glycoprotein (presumably at NBF1), we ¢nd that
NEM modi¢cation of NBF1 is su⁄cient to prevent
8-azido-ATP binding at NBF2. Taken together, these
results further con¢rm the strong cooperation be-
tween the two NBFs of P-glycoprotein. However,
they also indicate a possible non-equivalency of the
two NBFs in the function of P-glycoprotein.
Wild-type human P-glycoprotein contains seven
cysteines, and two of them are located in the WA
motifs of the NBFs. We replaced only these two
cysteine residues with alanine to avoid the allosteric
e¡ects which might be caused by replacing other cys-
teines. The C431A/C1074A mutant form of P-glyco-
protein was indistinguishable from the wild-type in
its function. Also the C431A/C1074A mutant P-gly-
coprotein trapped nucleotides even after treatment
with 100 WM NEM, indicating that the other ¢ve
cysteines were probably not accessible to NEM. In-
deed, none of the other cysteines were accessible to
biotin maleimide at 5 WM (Fig. 2). However, the
C431A/C1074A mutant P-glycoprotein showed an
increase in ATP binding after NEM treatment (Fig.
3B), indicating that NEM modi¢cation of other cys-
teine residues outside NBFs may allosterically a¡ect
ATP binding in a positive manner.
Liu and Sharom [17] have reported that Chinese
hamster P-glycoprotein is still able to bind ATP after
modi¢cation of two cysteine residues by 2-(4-malei-
midoanilino)naphthalene-6-sulfonic acid (MIANS).
However, NEM binding of both NBFs of human
P-glycoprotein impaired binding of 5 WM 8-azido-
ATP (Fig. 3A). We used 8-azido-[32P]ATP at 5 WM
to minimize non-speci¢c photolabeling. Higher con-
centrations of 8-azido-ATP might be able to bind the
NEM modi¢ed NBFs. Alternatively, the 8-azido
moiety may interact with the modi¢ed cysteine to
hinder ATP binding.
Muller et al. have reported a concentration de-
pendence of 8-azido-ATP binding to the WA lysine
mutant forms of P-glycoprotein [12]. They showed
that the mutation in a single NBF did not a¡ect 8-
azido-ATP binding but the double mutation reduced
8-azido-ATP binding. Fig. 4C shows that the WA
lysine mutation in NBF1 slightly reduced 8-azido-
ATP binding while the mutation in NBF2 slightly
increased it. In the experiments of Muller et al.
[12], P-glycoprotein was expressed in Sf9 insect cells.
Isolated cell membranes were used for the photoaf-
¢nity labeling. The membrane proteins were sepa-
rated on electrophoresis gels, and the photoa⁄nity
labeled band of P-glycoprotein was analyzed. We ex-
pressed P-glycoprotein-S and its mutant proteins in
HEK293 cells, and precipitated the photoa⁄nity la-
beled P-glycoprotein with S-protein agarose to elim-
inate other speci¢cally and non-speci¢cally photoaf-
¢nity labeled proteins. The slight di¡erences in these
results could be due to the di¡erent experimental
conditions.
The C431A mutant P-glycoprotein showed no
change in 8-azido-ATP binding after NEM treat-
ment. However, NEM treatment signi¢cantly re-
duced 8-azido-ATP binding in the C1074A mutant
P-glycoprotein. These results suggest that NEM
modi¢cation of NBF1 has an allosteric e¡ect on
ATP binding at NBF2 and is responsible for the
NEM inhibition of ATP binding in the wild-type
protein. However, NEM modi¢cation of NBF2
does not a¡ect further ATP binding presumably at
NBF1. This suggests that while the e¡ects of NEM
modi¢cation of the NBFs on vanadate-induced nu-
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cleotide trapping appear equal and cooperative, the
e¡ect on ATP binding is not.
Because nucleotide trapping of P-glycoprotein was
abolished when one NBF was modi¢ed or mutated,
the cooperative role of the two NBFs in the function
of P-glycoprotein may be equivalent as proposed by
Urbatsch et al. [9]. However, the roles of the two
NBFs in the function of SUR1 and CFTR appear
to be di¡erent [19,21,22], providing evidence for the
non-equivalency of the roles of the two NBFs in the
function of the ABC superfamily proteins. Our re-
sults, for the ¢rst time, also suggest that the NBFs of
P-glycoprotein may show some non-equivalency in
their function.
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